Clindamycin Phosphate
Brand names: Cleocin Phosphate, Clindacin P, Clindacin, Clindagel, Clindamycin Phosphate
At a glance
- Medicare prescriptions, 2024
- 434,958
- Medicare drug cost
- $16.0M
- Average cost per prescription
- $36.83
- Clinicians who prescribed it
- 15,282
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Clindacin ® (clindamycin phosphate) Foam, 1% is indicated for topical application in the treatment of acne vulgaris in patients 12 years and older.
From the FDA-approved prescribing information (label dated November 2022). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Dermatology 47.5%
- Physician Assistants 26.9%
- Nurse Practitioners 13.4%
- Family Medicine 3.6%
- Internal Medicine 3.1%
- Mohs Surgery 1.5%
- OB-GYN (Obstetrics & Gynecology) 1.1%
- Dermatopathology 0.8%
- Podiatrists 0.6%
- General Practice 0.4%
- Infectious Disease 0.1%
- Hematology & Oncology 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 37% from 2019 to 2024.
Biggest change by state since 2019
- Alabama +59%
- Colorado +58%
- South Carolina +54%
- Virginia +52%
- Indiana +51%
- Puerto Rico (smallest change) +13%
- Louisiana (smallest change) +17%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Medimetriks Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white aerosol | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
On the FDA shortage list now
- Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50) (Baxter Healthcare)
- Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50) (Baxter Healthcare)
- Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50) (Baxter Healthcare)
- Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50) (Baxter Healthcare)
- Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26) (Pfizer Inc.)
- Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26) (Pfizer Inc.)
- Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18) (Pfizer Inc.)
- Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09) (Sandoz Inc.)
2 recalls since 2020
- Aug 2026 · Baxter Healthcare Corporation · Class II
CGMP Deviations - Nov 2025 · Sun Pharmaceutical Industries Inc · Class III
Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.